| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 181.778 | 63.613 | 40.304 | 33.618 | 33.503 | -1.818 | 6.412 | 9.399 | 20.980 | 20.649 |
| Total Income - EUR | 182.704 | 64.709 | 96.879 | 34.173 | 44.892 | -1.273 | 9.830 | 11.112 | 21.116 | 20.650 |
| Total Expenses - EUR | 51.917 | 57.830 | 87.908 | 39.424 | 33.960 | 29.645 | 12.178 | 18.097 | 19.049 | 17.121 |
| Gross Profit/Loss - EUR | 130.787 | 6.878 | 8.972 | -5.251 | 10.932 | -30.918 | -2.348 | -6.985 | 2.068 | 3.529 |
| Net Profit/Loss - EUR | 108.564 | 5.646 | 7.187 | -5.589 | 9.589 | -30.936 | -2.638 | -7.323 | 934 | 2.862 |
| Employees | 3 | 3 | 3 | 3 | 1 | 0 | 0 | 0 | 1 | 1 |
Check the financial reports for the company - Aximed Pharmaceutical Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 57.174 | 68.870 | 23.379 | 18.719 | 27.660 | 23.229 | 19.712 | 21.412 | 12.463 | 12.630 |
| Current Assets | 66.782 | 44.951 | 106.250 | 89.012 | 31.838 | 5.858 | 5.626 | 15.857 | 11.927 | 12.381 |
| Inventories | 2.420 | 11.709 | 11.606 | 8.083 | 7.409 | 0 | 0 | 0 | 0 | 609 |
| Receivables | 8.842 | 8.794 | 6.934 | 6.651 | 9.073 | 1.143 | 234 | 128 | 2.168 | 193 |
| Cash | 55.520 | 24.448 | 87.710 | 74.279 | 15.355 | 4.716 | 5.391 | 15.729 | 9.759 | 11.579 |
| Shareholders Funds | 108.798 | 44.304 | 50.741 | 44.222 | 52.955 | 21.015 | 17.911 | 16.462 | 17.346 | 20.111 |
| Social Capital | 225 | 223 | 219 | 215 | 211 | 207 | 202 | 203 | 202 | 201 |
| Debts | 18.393 | 71.807 | 79.431 | 64.631 | 8.096 | 8.072 | 7.427 | 20.808 | 7.044 | 4.900 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4645 - 4645" | |||||||||
| CAEN Financial Year |
7022
|
|||||||||
Comments - Aximed Pharmaceutical Srl